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ABSTRACT 
Methotrexate has a clinically important pharmacokinetic interaction with 
nonsteroidal anti-inflammatory drugs (NSAIDs) mainly through its competition for 
tubular secretion via the renal organic anion transporter 3 (OAT3). We have 
previously reported the usefulness of OAT3-transfected renal tubular cells for 
screening of the drugs which interfere with the pharmacokinetics of methotrexate. 
Celecoxib, a cyclooxygenase (COX) 2 inhibitor, has not been reported to interact 
with methotrexate, but the mechanisms are unclear why the interaction is not 
occurred. The purpose of this study was to evaluate the effect of celecoxib on 
methotrexate tubular secretion using a renal cell line stably expressing human 
OAT3 (S2-hOAT3), and to evaluate the pharmacokinetic interaction of the two 
drugs in rats. [3H]methotrexate uptake into S2-hOAT3 cells was significantly 
inhibited by celecoxib in a concentration-dependent manner and the Ki value 
was 35.3 µM. However, methotrexate serum concentrations and urinary 
excretion of methotrexate over 24 h in rats were not affected by celecoxib (50, 
200 mg/kg). Celecoxib serum concentrations were increased by the increase in 
celecoxib dosage and the maximum drug concentration (Cmax) was 20.6 µM 
(celecoxib 200 mg/kg), which did not reach the Ki value obtained in the in vitro 
study. These results indicated that celecoxib inhibited the secretion of 
methotrexate via hOAT3, which suggested that celecoxib was a substrate of 
hOAT3. However, co-administration of the two drugs at clinical dosage did not 
affect the pharmacokinetics of methotrexate, because the serum concentrations 
did not reach the Ki value.  Although the accumulation study using S2-hOAT3 
cells was useful to predict the interaction between the new drug and 
methotrexate in vivo, a comparison of the Ki value with the Cmax in clinical 
  
dosage was necessary to evaluate the degree of this interaction.  
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1. Introduction 
Methotrexate and nonsteroidal anti-inflammatory drugs (NSAIDs) are 
often used concomitantly in clinical practice, such as for the treatment of 
rheumatoid arthritis and cancer. However, the combination is reported to 
increase methotrexate-related adverse effects (Daly et al., 1986; Frenia and 
Long, 1992; Shibayama et al., 2006; Tracy et al., 1992; Tuyss et al., 1986). 
Therefore, there is need of NSAIDs that do not elevate blood methotrexate 
levels for use in clinical pain management. 
Several mechanisms are known to be involved in the NSAID-induced 
increases in methotrexate concentrations (Ahern et al., 1988; Brouwers and de 
Smet, 1994; EI-Sheikh et al., 2007; Frenia and Long, 1992; Masada et al., 1997; 
Murray and Brater, 1993; Nozaki et al., 2007; Tracy et al., 1992; Uwai et al., 
2000; Uwai et al., 2004). In our previous study, we found that competition of 
tubular secretion via organic anion transporter-3 (OAT-3) is the most important 
mechanism on pharmacokinetic interaction between methotrexate and NSAIDs 
(Maeda et al., 2008), while others (such as competition for protein-binding sites 
and inhibition of cyclooxygenase in the kidney) are minor. Our results also 
showed that drug which did not inhibit the accumulation of methotrexate by the 
cells, had no potential interactions with methotrexate in the rats, Therefore, 
OAT3-transfected renal tubular cells are useful for screening of the drugs which 
interact with the pharmacokinetics of methotrexate. (Maeda et al., 2008).  
Celecoxib is a selective cyclooxygenase (COX) 2 inhibitor and it is 
reported that celecoxib had no significant effect on the pharmacokinetics of 
methotrexate in patients with rheumatoid arthritis (Karim et al., 1999). Celecoxib 
has a different chemical structure and higher value of pKa (pKa=11.1) as 
  
compared with other NSAIDs. Therefore, we speculated that celecoxib is not a 
substrate of OAT, which is the reason why celecoxib had no significant effect on 
the pharmacokinetics of methotrexate. The purpose of this study was to 
evaluate the competition between celecoxib and methotrexate by using proximal 
tubule S2 cells stably expressing hOAT3 (S2-hOAT3 cells) (Takeda et al., 2002) 
and then to examine the pharmacokinetic interaction between methotrexate and 
celecoxib using rats.  
  
  
2. METHODS 
2.1 Materials 
[3′,5′,7-3H]Methotrexate disodium salt (27. 7 Ci/mmol) and 
[methoxy-14C]inulin (3.5 mCi/mmol) were purchased from Moravek Biochemicals, 
Inc. (Brea, CA, USA). Acetaminophen, sulindac and loxoprofen were obtained 
from Sigma Chemical Co. (Tokyo, Japan). Celecoxib was kindly provided by 
Pfizer Inc. (Groton, CT, USA). S2-hOAT3 cells, which were established by 
introducing the human OAT3 gene into SV40-transfected mouse proximal tubule 
cells, were the generous gift of Dr. Endou (Kyorin University, Tokyo, Japan). This 
cell line highly and permanently expresses hOAT3 (Takeda et al., 2002). 
 
2.2 In vitro uptake examination 
The methods used to examine uptake of methotrexate into S2-hOAT3 
cells have been described previously (Maeda et al., 2008). In brief, S2-hOAT3 
cells were seeded in 12-well insert plates (3 μm, 8×105 pore/cm2: BD Falcon; 
Becton Dickinson Co., Lincoln Park, NJ, USA) at a density of 1×105 cells/well for 
7 days. Thereafter, the cells were incubated at the basolateral side for 2 h at 
37°C in FBS-free medium containing [3H]methotrexate (26 nM), [14C]inulin, and 
celecoxib, sulindac, loxoprofen,  acetaminophen or vehicle. When the uptake 
was finished, a 150-μl aliquot of the apical side medium was sampled, and its 
radioactivity was determined in 5 ml of ACS (Amersham Biosciences, 
Buckinghamshire, UK) by liquid scintillation counting. Samples in which 
[14C]inulin transited to the apical side (>1% of samples) were excluded. The 
uptake examination was stopped by cold phosphate-buffered saline (PBS) and 
the monolayer was rapidly washed 3 times adequately with cold PBS in each 
  
side. The cells in each well were dissolved with 150 μl of 1 N sodium hydroxide 
for 24 h at room temperature and were diluted 10 times with distilled water. The 
radioactivity of each sample (150 μl) was measured using the treatment 
described above. Samples in which [14C]inulin transited to the apical side (>1% 
of samples) were excluded. The protein content of the solubilized cells was 
determined using the bicinchoninic acid assay (Pierce, Rockford, IL, USA). We 
previously determined the accumulation of methotrexate in not-transfected cells 
(S2-DNA cells) (Maeda et al., 2008). We found that the accumulations of 
methotrexate in S2-DNA cells were extremely low and negligible as compared to 
OAT3-transfected cells. Furthermore, the accumulations of methotrexate in 
S2-DNA were not inhibited by the NSAIDs. 
Celecoxib, sulindac, loxoprofen and acetaminophen were dissolved in 
dimethyl sulfoxide (DMSO). Each drug was diluted with incubation medium. 
Adjustments were made so that the final concentration in the incubation medium 
was 0.1%. We preliminary found that low concentration (0.1%) of DMSO used in 
this study as vehicle did not interfere the transport of methotrexate in this cell. 
 
2.3 In vivo pharmacokinetic examination in rats 
Celecoxib, sulindac, and acetaminophen were suspended with 
tragacanth gum. Vehicle or an NSAID—celecoxib (50, 200 mg/kg), sulindac (50 
mg/kg), or acetaminophen (400 mg/kg)—was administered perorally to each 
fasting male wistar rat, weighing 265-286g (11-12 weeks old). After 30 min, 
methotrexate (40 mg/kg) (parenteral methotrexate 50 mg; Wyeth K.K., Tokyo, 
Japan) was administered as a bolus by intraperitoneal injection (He et al., 1991), 
and water (3% of body weight) was given orally to obtain enough urine. Each rat 
  
was housed individually in a rat metabolic cage during the experiment. In our 
previous study, the serum concentrations of NSAIDs were reached the Cmax 
within 30 min after oral administration of NSAID. This study is performed by 
following the previous study’s method (Maeda et al., 2008). We think that the 30 
min period is adequate time to observe the interaction with methotrexate 
because enough celecoxib was exposed in the plasma. 
The methods used for blood and urine collection have been described 
previously (Maeda et al., 2008). The protocol(s) were approved by the 
institutional ethics committee. 
  
2.4. Measurement of celecoxib 
Serum concentrations of celecoxib were determined by HPLC (Paulson et 
al., 1999). The chromatographic system (Jasco Co., Tokyo, Japan) consisted of 
an 880-PU intelligent pump equipped with an 880-51 two-line degasser, 851-AS 
intelligent autosampler, 875-UV intelligent UV detector, and CO-965 column 
oven. The column was a Mightysil RP-18 (4.6 × 150 mm, 5 µm; KANTO 
Chemical Co., Inc., Tokyo, Japan) fitted with an RP-18 guard column (4.6 × 5 
mm, 5 µm; KANTO Chemical) at 40°C. The mobile-phase flow rate was 
maintained at 1.0 ml/min for all drugs. 
The mobile phase was a mixture of acetonitrile and phosphate buffer (pH 
8.0), 5:5 (v/v). The UV wavelength was set at 250 nm. A serum volume of 50 μl 
was deproteinized by adding 150 μl of acetonitrile and vortexing for 30 seconds. 
After centrifugation at 12,000×g for 10 min at 4°C, 20 μl of the supernatant was 
injected onto the HPLC. 
 
  
2.5 Statistical analysis 
Data were analyzed statistically by one-way analysis of variance followed 
by Scheffe’s post hoc test (vs. vehicle). P values less than 0.05 were regarded 
as significant. 
  
3. RESULTS 
3.1 Inhibition of methotrexate accumulation in S2-hOAT3 cells by celecoxib  
We examined the inhibitory effects of celecoxib on methotrexate 
accumulation in S2-hOAT3 cells. As shown in Fig. 1, celecoxib inhibited the 
methotrexate accumulation mediated by hOAT3 in a concentration-dependent 
manner and the Ki value calculated from linear regression analysis with 
reciprocal of accumulation percent plot was 35.3 µM. We also confirmed our 
previous results in this cell line that 100 µM of sulindac and 100 µM of loxoprofen 
significantly inhibited the uptake of methotrexate, while acetaminophen did not. 
The effects of sulindac, loxoprofen and acetaminophen in this study were 
comparable with previous study (Maeda et al., 2008). 
 
 
 3.2 Interaction between methotrexate and celecoxib in rats 
As shown in Fig. 2, the serum methotrexate concentrations were not 
significantly changed by celecoxib (50 mg/kg, P = 0.1537; 200 mg/kg, P = 
0.2831) or acetaminophen (400 mg/kg; P = 0.9940). However, they were 
significantly increased by sulindac (50 mg/kg; P = 0.0028). We determined the 
serum celecoxib concentrations in rats administered celecoxib (50, 200 mg/kg) 
(Fig.3). The maximum drug concentration (Cmax) was 20.6 µM in the animals 
administered 200 mg/kg celecoxib.  
The percentage of methotrexate excreted in urine over 24 h was not 
affected by celecoxib and acetaminophen, but the urinary excretion of 
methotrexate was significantly increased over the period of 2-24 h (P < 0.05) by 
sulindac (Fig. 4). The effects of sulindac and acetaminophen in this study were 
  
comparable with our previous study (Maeda et al., 2008) 
  
4. DISCUSSION 
In our previous study, we established an in vitro screening system using 
S2-hOAT3 cells to evaluate the safety of NSAIDs coadministered with 
methotrexate. Our previous study suggested that a drug (e.g. acetaminophen) 
which did not inhibit methotrexate accumulation in vitro did not compete with the 
tubular excretion of methotrexate and did not affect the methotrexate 
pharmacokinetics(Maeda et al., 2008). 
In the present study, we determined the inhibitory effects of celecoxib and 
other NSAIDs using S2-hOAT3 cells, and we examined the pharmacokinetic 
interactions between celecoxib and methotrexate in rats at the concentration of 
methotrexate that is used during high-dose therapy (He et al., 1991). As shown 
in Figs. 1 and 2, sulindac, which inhibited the accumulation of methotrexate in 
S2-hOAT3 cells, increased the serum methotrexate concentrations, while 
acetaminophen, which exhibited no interaction in the in vitro study, also had no 
effect in vivo. These results were similar to those in our previous study. 
 It has been speculated that celecoxib, a selective COX-2 inhibitor, is not 
a substrate of OAT because it has a different structure and different physical and 
chemical properties as compared to other NSAIDs (Penning et al., 1997). In the 
present study, however, we found that celecoxib inhibited methotrexate 
accumulation in vitro mediated by hOAT3 in a concentration-dependent manner. 
These results suggested that tubular secretion of methotrexate via hOAT3 was 
inhibited by celecoxib. On the other hand, we found that serum methotrexate 
concentrations and urinary excretion of methotrexate over 24 h were not affected 
by celecoxib in this study. We also measured the celecoxib concentrations in rats 
following administration of 50 or 200 mg/kg of the drug (Fig. 3). It was revealed 
  
that the celecoxib concentrations were below the Ki value obtained by in vitro 
study. These results indicated that celecoxib inhibited the methotrexate tubular 
secretion via hOAT3 but pharmacokinetic interaction is not observed at present 
dose because serum concentration of celecoxib is not reached to Ki value. 
Therefore, even if we observed inhibition of methotrexate accumulation in 
S2-OAT3 cell in vitro, drug interaction at renal tubular secretion in vivo will not be 
observed if serum drug concentration is not approaching the Ki value. If the dose 
of celecoxib was increased and its concentrations were higher than Ki value, the 
pharmacokinetic interaction with methotrexate might have appeared. Although 
inhibition of methotrexate accumulation in S2-hOAT3 is useful to evaluate 
possible pharmacokinetic interaction with methotrexate in vivo, this analysis 
becomes less useful if such inhibitory levels in vivo cannot be achieved. 
It has been reported that total plasma celecoxib concentrations were 
below 1.42 µM in human volunteers who received a single application of 200 mg 
celecoxib (Jayasagar et al., 2002) and were 10.5 µM in those who received 600 
mg BID for 7 days (Paulson et al., 1999). Considering Cmax obtained in this 
study and these literatures, the dose of 50 mg/kg celecoxib in rat appeared to be 
comparable to the clinical dose in humans, whereas the dose of 200 mg/kg 
celecoxib in rats corresponded to a supra-therapeutic dose in humans. In a 
previous report, when the dose of celecoxib was increased up to 400 mg/kg in 
rats, the Cmax was reported to be 17.7 µM (Paulson et al., 1999), which was 
comparable with our results. In these reports, the celecoxib concentrations did 
not reach the Ki value even at supra-clinical dosage.  
In general, the interaction between methotrexate and NSAIDs is known to 
involve multiple processes. In addition to the inhibition of methotrexate tubular 
  
secretion by NSAID, It has been reported that NSAID decreased glomerular 
filtration of methotrexate via a reduction of renal blood flow with inhibition of 
prostaglandin and the NSAID also competed for protein-binding sites of 
methotrexate (Ahern et al., 1988; Brouwers and de Smet, 1994). However, we 
have previously found that contributions of these two factors were relatively 
small for pharmacokinetic interaction and competition of renal tubular secretion 
was the major factor to determine the pharmacokinetics. hOAT3 is the main 
transporter at basolateral membrane for uptake of methotrexate from the blood 
fluid and its mRNA expression level is the highest among the OAT family 
(Motohashi et al., 2002; Takeda et al., 2001). However, all mechanisms of 
pharmacokinetic interaction cannot be explained merely by the competition for 
hOAT3. It is necessary to consider the contribution of other transporters of these 
drugs at the apical membrane of the kidney tubule. (Shibayama et al., 2006; 
Takeuchi et al., 2001; Van Aubel et al., 2000). Furthermore, it is also necessary 
that the contribution of the interaction between methotrexate and celecoxib 
metabolites is considered. Celecoxib is rapidly metabolized in rats via oxidative 
pathway and almost excreted in the feces within the 24h (Paulson, Zhang et al, 
2000). The metabolism of celecoxib in rats is similar to the humans occurring 
primarily through a single metabolic pathway. 
There is a difference on substrate specificity between hOAT3 and rOAT3 
(Cha et al. 2001: Hasazawa et al. 2002). We did not have any data about direct 
comparison between hOAT3 and rOAT3 in celecoxib/MTX transport and we think 
this is a limitation of this study. However, in our previous study, serum 
methotrexate concentrations were increased in the rat when concentrations of 
NSAIDs were more than the Ki values obtained by hOAT3-uptake studies. Thus, 
  
our in vitro data with hOAT3-expressing cells can be used in evaluating renal 
pharmacokinetic interactions in rats. This finding is compatible with a previous 
report that the character of OAT3 in humans is comparable to that in rats 
(Matsumoto et al. 2007). We think this in vitro study provides useful information 
when we consider the pharmacokinetic drug interaction in humans. 
In conclusion, celecoxib inhibited the methotrexate tubular secretion via 
OAT3 and this result suggested that celecoxib is a substrate of hOAT3. However, 
celecoxib did not show any pharmacokinetic interaction with methotrexate in vivo 
in clinical dosage mainly because serum concentrations of the drug was smaller 
than the Ki value obtained from the in vitro study. To predict the magnitude of the 
pharmacokinetic interaction between methotrexate and the new drug by in vitro 
study, it is necessary to obtain not only the Ki value by in vitro study but also the 
drug’s therapeutic concentrations. It could be presumed that any drug 
administered at a therapeutic concentration less than the Ki value will show little 
interaction with methotrexate. Therefore, our accumulation study using 
S2-hOAT3 cells might be useful for screening potential interactions between 
methotrexate and new drugs in vivo, provided that inhibitory concentration can 
be achieved in vivo. 
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FIGURE LEGENDS 
Fig. 1. Effects of celecoxib and other NSAIDs on [3H]methotrexate accumulation 
in S2-hOAT3 cells. The results are presented as the means ± S.D. (n =6). *P < 
0.01 vs. vehicle. 
 
Fig. 2. Serum methotrexate concentrations after intraperitoneal injection of 
methotrexate. The results of each plot are presented as the means ± S.D. (n = 6). 
Celecoxib 50 mg/kg (●), 200 mg/kg (○); sulindac 50 mg/kg (▲); 
acetaminophen 400 mg/kg (△); vehicle (■). *P < 0.01 vs. vehicle. 
 
Fig. 3. Celecoxib concentrations in serum after intraperitoneal injection of 
methotrexate. The results of each plot are presented as the means ± S.D. (n = 
6): celecoxib 50 mg/kg (●), 200 mg/kg (○). 
 
Fig. 4. Percentage of methotrexate excreted in urine. The results are presented 
as the means ± S.D.  *P < 0.05, **P < 0.01 vs. vehicle. 
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